, Columnist
Mallinckrodt's Worries Aren't Over
The specialty pharma firm is overly dependent on this old, expensive drug.
This article is for subscribers only.
It didn't take long for the first specialty pharma scandal of 2017 to materialize.
Mallinckrodt PLC on Wednesday disclosed it will pay $100 million to settle FTC charges that Questcor Pharmaceuticals, which Mallinckrodt bought in 2014, illegally raised the price of its best-selling drug Acthar by 85,000 percent and bought the rights to a cheaper competing drug to keep it out of the U.S. market. The settlement forced Mallinckrodt to give a free limited U.S. license for that cheaper drug to a competitor, Marathon Pharmaceuticals.